Press Releases
-
May 31, 2018
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that the...
-
May 31, 2018
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, has elected Hong Yu as...
May 25, 2018Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that Dr....
-
May 10, 2018- Steady progress in the new year signals strengthening financial and technology positions
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its...
-
May 4, 2018- Conference Call with Live Audio Webcast on Thursday, May 10th at 9:00 AM ET -
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it...
Apr 2, 2018- Fourth Quarter Headcount Reduction and Private Placement Extend Operational RunwayBiostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and...
Mar 29, 2018Biostage Names Distinguished Children's Hospital Executive James Shmerling to its Board of DirectorsBiostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
-
Mar 29, 2018- Potential to provide up to $1.7 million of nondilutive funds to support pre-clinical testing of Company's pediatric esophageal implant product candidate
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced it has...
-
Mar 13, 2018Large-animal study results published in Nature Scientific Reports show successful esophageal regeneration
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the publication of...
-
Feb 20, 2018
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the previously disclosed...
Feb 12, 2018Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat conditions of the esophagus, bronchus and trachea, today announced the appointment of Charles...
Feb 7, 2018Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that it...
-
Feb 6, 2018- Conference Call with Live Audio Webcast on Tuesday, February 13th at 9:00 AM ET -
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced that on...
-
Jan 31, 2018
Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced the...
-
Jan 3, 2018- Investors strongly back technology, advancement to the clinic in U.S. Market-
Biostage, Inc. (OTCQB: BSTG/BSTGD), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Dec 22, 2017- Required for financing agreement -
Biostage, Inc. (OTCQB: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Dec 14, 2017- Investment will provide path forward for Biostage -
Biostage, Inc. (OTCQB: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Oct 12, 2017- Emphasizes Robustness of its Technology Despite Financial Uncertainty -
Biostage, Inc. (OTC-QB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Oct 6, 2017- Delisted from NASDAQ effective October 6, 2017 -
Biostage, Inc. ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and...
-
Oct 2, 2017- Presentation with live video webcast Thursday, October 5th at 4:45PM PDT -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening...
-
Aug 14, 2017Closes $3M private placement
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 7, 2017- Procedure approved via the FDA's single-use expanded access program and was performed at a major U.S. hospital -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening...
-
Aug 4, 2017- Conference Call with Live Audio Webcast on Monday, August 14th at 9:00 AM ET -
Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Jul 10, 2017
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
-
Jun 27, 2017- Strategic investor provides opportunity through future rights offering for additional gross proceeds up to $14 million -
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
